Project Grant R42HL174259
Award Date
9/16/24
Completion Date
9/15/25
Dollars Obligated
$657K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Evanston, IL 60201, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $294,023 to Heartlung Corporation to develop and validate an FDA-designated breakthrough AI tool called AUTOCHAMBER. The AUTOCHAMBER AI is designed to opportunistically screen existing chest CT scans to detect enlarged cardiac chambers and thickened left ventricular walls, which can indicate increased risk of atrial fibrillation,...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $443,544 to Dasisimulations LLC to develop and validate an AI-driven software platform for automating critical measurements required for pre-planning transcatheter aortic valve replacement (TAVR) procedures. The software leverages convolutional neural networks to automatically extract necessary anatomical measurements from CT imaging data, reducing the...
The National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded a $321,363 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Nucleusrx, Inc. located in Cranbury, NJ. The purpose of this 1-year project is to develop and test Nucleusrx's virtual care platform and remote intervention tool targeting post-acute care heart failure (HF) patients. The goal is to provide a safe and cost-effective discharge transition...
This Project Grant award of $810,650 from the National Heart Lung and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports research at Cedars-Sinai Medical Center to develop and validate an AI-enabled algorithm for characterizing fibrotic and calcific aortic valve tissue from computed tomography angiography (CTA) scans. The goal is to predict rapid aortic valve disease progression and patient outcomes following valve replacement surgery. The project...
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), awarded a $299,604 project grant to Case Western Reserve University. The 4-year grant, effective September 1, 2024, supports the development and validation of a novel "transfer volume regression" model to enable quantitative clinical risk predictions for major cardiovascular events, including stroke, heart attack, heart failure, and death. The project...
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), awarded a $306,748 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Mechanobiologix LLC. The award, with a performance period from September 2024 to September 2025, supports the development of a stiffness-based drug discovery platform to evaluate therapeutic and preventive capabilities of anti-fibrotic drugs for Idiopathic Pulmonary Fibrosis (IPF). The...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $2,095,816 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The DNA Medicine Institute, Inc. to develop a rapid, 5-minute point-of-care test that can measure anti-Factor Xa activity and hemoglobin levels. This diagnostic tool is intended to guide emergency management for patients on direct oral anticoagulants, potentially enabling quicker delivery of life-saving interventions. The 2-year project,...
The National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded a $691,708 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Mayo Clinic in Rochester, Minnesota. The purpose of this 5-year project is to develop a novel, contrast-free ultrasound-based quantitative angio flow imaging technique, named Angio Flow Reactivity Analysis (AFRA), to assess peripheral arterial disease (PAD) of the lower limbs. The key...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $691,326 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to Northwestern University to develop a "4D Right-Heart Virtual Catheter (4D VCATH)" technology. This innovative approach combines advanced mathematical modeling and 4D flow MRI to provide a comprehensive, non-invasive hemodynamic analysis of the right heart chambers for the diagnosis, classification, and prognosis of pulmonary...
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), awarded a $1,557,275 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Utah. The funding will support the development of a novel magnetic resonance imaging (MRI) method to detect coronary artery disease (CAD) in patients with atrial fibrillation (AFib). Specifically, the project aims to create a flow and motion insensitive steady-state (FAMISS)...